Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).

Leukemia research - 1 Aug 2024

Galieni Piero, Troiani Emanuela, Picardi Paola, Angelini Mario, Mestichelli Francesca, Dalsass Alessia, Maravalle Denise, Camaioni Elisa, Bigazzi Catia, Caraffa Patrizia, Ruggieri Miriana, Mazzotta Serena, Mattioli Silvia, Angelini Stefano

Abstract excerpt

The mutational status of the IGHV gene is routinely assessed in patients with chronic lymphocytic leukaemia (CLL), since it is both prognostic of clinical outcome and predictive of response to treatment. This study evaluates the IGHV mutational status, assessed in newly diagnosed CLL patients, as a stand-alone predictor of time to first treatment (TTFT). We analysed the data of 236 CLL patients, diagnosed at our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Variable Region

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Neoplasm Staging

Share to Prognosis

Source

Identifiers

PMID: 38905908
DOI: 10.1016/j.leukres.2024.107541

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).PMID 38905908Read ↗

Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.Semantic proximity Read ↗

Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.Semantic proximity Read ↗

Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patientsSemantic proximity Read ↗

Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.Semantic proximity Read ↗

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.Semantic proximity Read ↗

Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.Semantic proximity Read ↗

Prognostication in chronic lymphocytic leukemia.Semantic proximity Read ↗

Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.Semantic proximity Read ↗

Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.Semantic proximity Read ↗

MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.